When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AIM - AIM ImmunoTech +34% after FDA authorizes ampligen trial in COVID-19 patients
AIM ImmunoTech Inc.
The FDA has authorized AIM ImmunoTech (NYSEMKT:AIM) the first human trial assessing the safety and effectiveness of Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19.
More news on: AIM ImmunoTech Inc., Healthcare stocks news, Stocks on the move,